SPIRIT II Yields Mixed Results For Xience Drug-Eluting Stent

Boston Scientific and Abbott are emphasizing the safety and clinical effectiveness of the Xience V everolimus-eluting stent shown in the SPIRIT II trial while downplaying the disappointing angiographic results